Plain-English translation of NCT07118176 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging tracer called 68Ga-FAPI-46 to see how well it can detect cancer in the body. The medication is injected into your bloodstream, and then special imaging scans show where it collects in cancer tissues. Researchers want to understand how this new tracer compares to an existing imaging method currently used in cancer care.
Current cancer imaging methods don't always detect all tumors clearly, and doctors need better tools to find and monitor cancer. This study will help determine if this new imaging tracer could become a more effective way to identify cancer throughout the body.
You will receive an injection of the new imaging tracer into your vein. About 20 to 90 minutes later, you'll have a PET/CT scan that takes 20 to 50 minutes, during which you'll need to lie still while the scanner takes images. You may also be offered an optional second imaging scan to compare results. The study involves one or a few visits depending on whether you choose the optional scan.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States